At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
acalabrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating acalabrutinib for Multiple Myeloma (MM). Completed, enrolled 27 participants across 3 sites in 2 countries.
Detailed Summary
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma (MM)
CountriesUnited Kingdom, United States
CollaboratorsAcerta Pharma, LLC
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartFeb 2015
Primary CompletionApr 2019
TodayJul 2026
First PostedAug 7, 2014
Enrollment StartFeb 1, 2015
Primary CompletionApr 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.9 years ago
Interventions
acalabrutinibdrug